NewsSource: EClinCloud Official Website Archive

EClinCloud Interview with VCBeat: Building an Integrated Intelligent Cloud Platform to Address Clinical Trial Digital Transformation Challenges

9 min readEClinCloud Editorial Team
EClinCloud Interview with VCBeat: Building an Integrated Intelligent Cloud Platform to Address Clinical Trial Digital Transformation Challenges — Archived Article Cover

Recently, Dr. Qin Long, CEO of EClinCloud, gave an exclusive interview to a VCBeat reporter. Below is the interview.

 

A significant gap has long existed in the digitalization of clinical trials in China.

 

Under dual pressures from policy and the market, the pharmaceutical industry is focusing on optimizing sales models and improving R&D efficiency. Healthcare SaaS vendors develop products by capturing and integrating data inflows and extensive accumulated data across these two areas to increase the success rate of clinical drug development, improve clinical trial quality, and shorten R&D cycles.

 

On the one hand, the Chinese market has long been dominated by foreign pharmaceutical R&D SaaS vendors represented by Medidata, Veeva, and Oracle, and there has been a lack of pharmaceutical R&D SaaS solutions that can truly address the needs of domestic pharmaceutical companies and deeply understand their pain points. On the other hand, within China's digital clinical research industry, many vendors focus on specific segments, while relatively few companies can truly provide integrated solutions.

 

EClinCloud (Shenzhen) Technology Co., Ltd. (hereinafter "EClinCloud") is positioned as an integrated clinical evidence support SaaS cloud platform, seeking to build further upon existing solutions; at the same time, as a strategic partner of the international clinical evidence support company Signant Health, it is responsible for full business operations in Greater China. Based on client needs, it promotes eCOA (electronic clinical outcome assessment) software and services.

 

Reportedly, its eCOA solution has been used in more than 2500 clinical trials worldwide, covering approximately 100 × 10,000 patients and serving over 1000 organizations.

 

n  Building an integrated architecture to achieve data interoperability

 

Generally speaking, pharmaceutical R&D SaaS is an industry that places strong emphasis on user reputation, where leading companies can readily draw on accumulated user requirements to iterate their products rapidly, creating a snowball effect. As a result, resources in pharmaceutical R&D SaaS tend to concentrate around leading players.

 

However, within a short period of time, the startup EClinCloud built an integrated pharmaceutical R&D SaaS solution and, through the integrated platform, has addressed current industry problems such as information silos, the inability to transfer data across different systems, and low accuracy in manual verification, further improving clinical research efficiency. At the same time, it further provides a foundation for cross-application, cross-project, and cross-user big data analysis.

 

In the view of EClinCloud founder Qin Long, a growth path of entering at certain key stages and then extending upstream and downstream can easily leave pharmaceutical R&D SaaS companies, as they expand their service scope, facing challenges such as insufficient synergy between new and existing services and difficulty achieving system and data interoperability in the final solution. Therefore, for pharmaceutical R&D SaaS companies, "begin with the end in mind" is the best development strategy to overcome this challenge.

 

Qin Long further explained: "To help pharmaceutical companies obtain reliable clinical endpoint assessment results, pharmaceutical R&D SaaS companies need to start from the entire new drug R&D workflow, including data generation, data collection, and data analysis. At the same time, they need to build the overall product architecture around this process under strict standard requirements to help clients obtain solutions consistent with clinical endpoint results to the greatest extent possible. During this process, considering future post-interconnection scenarios in advance is also especially important; companies must not only broaden product coverage, but also consistently maintain unified data standards and interoperability across data."

 

Based on this understanding, EClinCloud aims to ultimately build a "patient-centric," "data-driven" integrated clinical evidence support SaaS platform, genuinely improving clinical research efficiency for pharmaceutical companies.

 

Currently, the company has completed building its integrated platform, and this integrated platform is mature, having been validated across over a hundred projects. Next, on this foundation, EClinCloud will continue to build a DCT platform to enable remote conduct from patient informed consent, data collection, and project technology to physician endpoint assessment.

 

n  Starting from patient data, operational data, and industry data to ultimately build a "data-driven" business platform

At the current stage, EClinCloud has reportedly refined its overall system build centered on the eCOA system.

 

EClinCloud's eCOA system can provide pharmaceutical companies with an extensive library of standard scales while supporting complex logic checks. Through correlations between questions across scales, it helps raters promptly identify data anomalies. In addition, sponsors, CROs, and study sites can all access and view data in real time through reporting tools across different dimensions.

 

RTSM (randomization and drug management system), MAMS (device transfer system), and CTMS (clinical trial project management system) can assist pharmaceutical companies with clinical trial project management.

 

In addition, EClinCloud provides pharmaceutical companies with related supporting services such as scale management, rater training and qualification, and study build and configuration to address issues pharmaceutical companies face during final product approval, such as lack of copyright licensing for scales, scale digitization, and subjectivity in scale results.

 

With support from international experts, EClinCloud will also add new modules such as Sensor Link (wearable device data acquisition) to its existing products to further optimize its enterprise solutions. It will expand its business in areas such as scale services, back-end medical support, rater training, and endpoint assessment for multicenter clinical trials.

 

For example, with modules such as wearable devices and electronic informed consent, patient data can be transmitted directly to the EClinCloud system through supporting devices without requiring patients to enter the data themselves. This can further ensure the accuracy and objectivity of patient data. Meanwhile, its electronic informed consent, remote monitoring system, and other modules can help companies reach patients more effectively.

 

At the same time, EClinCloud also plans to ultimately build a "data-driven" business platform by the end of 2024, delivering data-value applications to clients, extending the breadth and depth of its products, and making the EClinCloud business platform a truly intelligent platform.

 

Regarding this, Qin Long noted: "Achieving true data interoperability is very difficult, yet it is currently the biggest challenge facing nearly all pharmaceutical companies. Therefore, EClinCloud aims to reach this goal through a 'data-driven' approach. Specifically, through an integrated platform system, it captures authentic and reliable patient data, operational data, and industry data, and uses these three dimensions of data to assist pharmaceutical companies in obtaining more accurate clinical endpoint assessments and conducting clinical programs digitally."

 

n  Establishing an Independent Medical Department to Provide Support in Laws and Regulations, System Design, and Related Areas

To truly help clients obtain more accurate clinical endpoint assessments—and ultimately increase the success rate of clinical drug development, improve clinical trial quality, and shorten R&D timelines—EClinCloud has assembled a team with a deep understanding of clinical research and established an independent medical department to provide specialized support, including in laws and regulations, for new drug development. This enables the company, from the very outset of product design, to build a platform, underlying architecture, product features, and related components that meet the regulatory requirements of authorities worldwide.

 

Dr. Qin Long, founder of EClinCloud, has more than 16 years of experience in technology applications within the clinical research industry. He took the lead in promoting and implementing digital clinical solutions in China's clinical trial research field, and previously served as Head of Business Development for Asia-Pacific at Signant Health, planning business development across the region. After he left to start his own company, Signant Health entrusted its Asia-Pacific business to Dr. Qin Long, fully demonstrating the trust between the two parties.

 

Qin Long told VCBeat: "Our collaboration with Signant Health gives EClinCloud a stronger advantage in international business. EClinCloud's platform design, product features, and delivery standards are all established in accordance with international standards, which also lays the foundation for EClinCloud to take on broader market demand in the future."

 

EClinCloud's Chief Technology Officer has over 30 years of experience in IT across the healthcare, financial, and manufacturing industries, having previously served in C-level executive roles at major companies such as Oracle, Hitachi Data Systems, and IBM, with extensive experience in IT infrastructure and SaaS platform development.

 

The Chief Medical Officer has over 17 years of medical, clinical operations, and quality management experience in clinical research. At a well-known innovative pharmaceutical company, the Chief Medical Officer previously led teams in formulating and executing global clinical development strategies for core products that successfully obtained marketing approval in both China and the United States, and is well-versed in common electronic clinical trial systems in China and internationally, such as EDC, CTMS, eTMF, and eCOA.

 

The EClinCloud team's medical capabilities also set it apart among peers in the same field.

 

EClinCloud's medical team understands the rigor of clinical research and clearly knows where during the clinical research process it can help sponsors improve study efficiency and thereby reduce the risk of drug development failure. As a result, EClinCloud's products naturally align more closely with real-world clinical research scenarios, helping pharmaceutical and medical device companies genuinely reduce costs, improve efficiency, shorten drug development cycles, and increase the success rate of drug development. Following two years of dedicated refinement, EClinCloud has begun serving relevant projects and supporting companies' product studies.

 

n  In closing

Over the past 5 years, Chinese pharmaceutical companies have placed increasing emphasis on post-marketing studies and conducted a large number of them. However, the vast majority of companies have not standardized, cleaned, and merged the data obtained from these studies. By contrast, major multinational corporations such as Pfizer invest substantial funds each year in standardizing clinical research data to maximize product value and extend product lifecycles. Clearly, conducting new drug R&D through digital and intelligent approaches has become the prevailing trend for the future.

 

The release of policies such as the "4+7" volume-based procurement program, consistency evaluation, and DRGs medical insurance cost containment has further compelled pharmaceutical companies to pursue digital transformation in clinical research. At a critical juncture in the upgrading of the pharmaceutical industry, the market needs pharmaceutical R&D SaaS solutions that can genuinely address the needs of pharmaceutical companies and deeply understand their pain points. Built around technological innovation and a precision medicine evaluation framework, the "patient-centric," integrated clinical evidence-support SaaS cloud platform developed by EClinCloud is certainly not without significance.

 

In the future, EClinCloud will also establish long-term business partnerships with major biotechnology companies, CRO companies, large pharmaceutical companies, small and medium-sized pharmaceutical companies, and multinational corporations to build an industry ecosystem, further expand business channels, and rapidly cover the entire industry.

 

This article is reposted from VCBeat. Please contact us if you wish to reprint it.

Related reading

Archived article cover: With Rising Pharmaceutical Submissions and Tightening Investment, How Can Digital Solutions Help Clinical Research Reduce Costs and Improve Efficiency?News7 min readWith Rising Drug Filings and Tightening Investment, How Can Digital Solutions Help Reduce Costs and Improve Efficiency in Clinical Research?As the biopharmaceutical industry continues to develop, innovative drug R&D has entered a period of rapid growth, and the number of clinical drug trials is trending upward. Alongside this, improving clinical trial efficiency and reducing the costs and risks of clinical research have become urgent priorities for a growing number of pharmaceutical companies and research institutions. Using digital tools to advance the digital and intelligent development of clinical trials is undeniably the prevailing trend. To better meet the needs of digital and intelligent clinical development and share the latest achievements and solutions, EClinCloud recently convened in Chengdu its first User Conference, "Digital and Intelligent Empowerment: Symbiosis and Win-Win," bringing together pharmaceutical industry leaders for discussions.Article cover for "Scale scoring: a different score from every rater? An overview of the history of neuropsychological scale assessment"News8 min readInconsistent Scale Scoring? Understanding Neuropsychological Scale AssessmentIn neurology, neuropsychological assessment is an indispensable tool in clinical diagnosis and research. However, during clinical scale assessments, raters may apply varying degrees of subjective judgment and interpret the scales inconsistently, leading to differences in scoring outcomes; if a rater uses leading language or questions during the assessment, this can also introduce bias into the results. In the field of neuropsychology in particular, neuropsychological assessment results often serve as the primary endpoint of clinical trials; biased results may reduce a clinical trial's reliability and, in severe cases, lead to study failure. Therefore, standardized training on the use of neuropsychological assessment scales is necessary to...Archived article cover: EClinCloud eCOA system passes CFDI inspection, supporting marketing approval of Raynovent's COVID-19 treatment leritrelvir tabletsNews4 min readEClinCloud eCOA System Passes CFDI Inspection, Supporting Marketing Approval of Raynovent's COVID-19 Treatment Leritrelvir TabletsOn March 23, 2023, in accordance with the relevant provisions of the Drug Administration Law and under the special drug approval procedures, the National Medical Products Administration (NMPA) granted conditional marketing approval to leritrelvir tablets (brand name: Leruiling), a Category 1 innovative drug submitted by Guangdong Raynovent Biotech Co., Ltd. (hereinafter referred to as "Raynovent"). The drug is an oral small-molecule therapy for novel coronavirus infection, indicated for the treatment of adult patients with mild-to-moderate novel coronavirus infection (COVID-19).